N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration.
Talley
J J
JJ
Searle Research and Development, 700 Chesterfield Parkway, St. Louis, Missouri 63198, and 4901 Searle Parkway, Skokie, Illinois 60077, USA. john.j.talley@monstanto.com
Bertenshaw
S R
SR
Brown
D L
DL
Carter
J S
JS
Graneto
M J
MJ
Kellogg
M S
MS
Koboldt
C M
CM
Yuan
J
J
Zhang
Y Y
YY
Seibert
K
K
D000215:Acylation; D000818:Animals; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs; D007267:Injections; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D007555:Isoxazoles / Q000008:administration & dosage / Q000494:pharmacology*; D008252:Macaca fascicularis; D008297:Male; D011451:Prostaglandin-Endoperoxide Synthases / Q000494:pharmacology*; D051381:Rats
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007555:Isoxazoles; C409945:parecoxib; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases